PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

• References

• 1 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
• 2 Reny JL, de Moerloose P, Dauzat M. et al. Use of the PFA-100 trade mark closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
• 3 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 4 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
• 5 Di Castelnuovo A, Soccio M, Iacoviello L. et al. “The C242 T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and meta-analyses. Thromb Haemost 2008; 99: 594-601.